IMR Press / FBL / Volume 18 / Issue 1 / DOI: 10.2741/4103

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

BlyS: a potential hallmark of multiple myeloma
Show Less
1 Shanghai JiaoTong University School of Medicine, Xinhua Hospital, 1665 Kongjiang Road, Shanghai 200092, China
2 Shanghai JiaoTong University School of Medicine, Shanghai Institute of Immunology, 227 South Chongqing Road, Shanghai 200025, China
3 Shanghai JiaoTong University School of Medicine, Ruijin Hospital, 197 Ruijin Er road, Shanghai 200025, China
Front. Biosci. (Landmark Ed) 2013, 18(1), 324–331;
Published: 1 January 2013

Multiple myeloma (MM) is a plasma cell dyscrasia characterized by bone lesions and production of a paraprotein. B-lymphocyte stimulator (BLyS) and its receptor (BAFFR) were highly expressed on peripheral blood and bone marrow B cells in MM patients as compared to those with monoclonal gammopathy of unknown significance (MGUS) and healthy donors. Serum BLyS levels in MM patients were significantly higher than those in MGUS patients and healthy controls. BLyS expression was increased in bone marrow specimens from MM patients as ascertained by immunofluorescence. Furthermore, BLyS, together with IL-2 and IL-6, significantly promoted MM cell proliferation and BLyS receptor expression compared with that in the control group. Treatment with bortezomib, a therapeutic proteasome inhibitor induced apoptosis and repressed the proliferation of RPMI8226 and U266 cells through inhibition of NF-κB p65 and IκBα. These findings suggest that BLyS is involved in the immunopathogenesis of MM and may prove to be a hallmark of MM.

Multiple myeloma
B-lymphocyte stimulator
Back to top